CONCLUSION:
We measured a 14% sensitization rate to the D antigen in our RhD-negative oncology population. The rate of alloimmunization was higher in patients who had solid cancers (22.6%) or myelodysplastic syndrome (23%) compared with those who had other hematologic malignancies (7%). Knowledge of diagnoses that predispose to RhD alloimmunization enables better utilization of RhDnegative RBCs during times of shortage. R hD is a potent immunogen. As little as 0.03 mL of RhD-positive red blood cells (RBCs) can immunize an RhD-negative recipient. 1 The earliest studies on healthy RhD-negative volunteers who were exposed to RhD-positive RBCs reported alloimmunization rates of more than 80%. 2, 3 Subsequent studies in both oncology and nononcology patients showed that alloimmunization rates were much lower (Table 1) . In nononcology patients, the alloimmunization rate of D-negative patients exposed to D-positive RBCs was 22%. 11 The true incidence may have been overestimated in that study, because it included patients who had positive antibody screens less than 28 days after receipt of the first Rh-incompatible transfusion. The earliest time reported in the literature to produce an anti-D immune response (which was immunoglobulin [Ig]G) was 28 days, and formation of anti-D before this time point has generally been considered an anamnestic response. 19, 24, 26 However, it should be mentioned that the switch from IgM to IgG occurs so early that the first detectable antibody by serological tests in Rh immunization is typically IgG.
Only specially treated RBCs reportedly have resulted in detectable anti-D within 14 days. 28 In contrast, alloimmunization to RhD in oncology patients was lower and ranged from 0% to 12.3%. [13] [14] [15] The explanation for this is that patients with cancer have varying degrees of immunosuppression, and chemotherapy can cause transient diminution of innate, humoral, and cell-mediated immunity. However, a major limitation to studies in oncology patients is that alloimmunization was evaluated only with regard to platelets and/or granulocytes and did not include RBCs. Because of the limited availability of RhD-negative blood components in cancer centers with high demand for hemotherapy support, RhD-positive blood may be issued to RhD-negative patients. Based on our previously published experience, we observed an extremely low rate of alloimmunization to RhD-incompatible transfusions (4%) in patients with hematologic malignancies. 10 Therefore, during inventory constraints, RhD-negative women of childbearing potential are given first preference of O-negative RBCs followed by RhD-negative patients with solid malignancies, because they are at high risk to form anti-D. Given the very low rate of anti-D formation in RhD-negative patients with hematologic malignancies, O-positive RBCs are given to these individuals, and this practice is continued until the inventory shortage is alleviated. We analyzed the clinical factors associated with anti-D formation in oncology patients after RBC transfusion.
MATERIALS AND METHODS
This retrospective, epidemiological study evaluated the alloimmunization rate to RhD-positive RBCs at a single comprehensive cancer center from January 2011 to December 2014. There was no control group of nononcology patients. Eligibility criteria included RhD-negative oncology patients who had no anti-D identified before the study dates, had received transfusion of at least one RhDpositive RBC unit, and had a follow-up RBC antibody screen obtained at least 28 days after transfusion. No anti-D Ig was administered to any of the patients during the study period.
Because of logistical constraints, RhD-incompatible platelet (mainly whole blood-derived), plasma, granulocyte, and cryoprecipitate transfusions were not included in the current study. A nonresponder was defined as someone who had no detectable anti-D on an antibody screen obtained at least 28 days or more after transfusion of RhD-incompatible RBCs. All patients who had followup type and screen results available less than 28 days after transfusion of RhD-positive units were excluded, because their response to RhD was considered anamnestic.
We extracted data for all RhD-incompatible RBC transfusions from our blood bank information system (MAK-Systems) during the study period and reviewed patients' electronic medical records (ClinicStation; institution-specific product). We recorded clinical factors, such as age, sex, race, ABO group, immune status (to 
RESULTS

Patient characteristics
Patient characteristics are detailed in Table 2 . All patients with solid malignancies, including carcinomas, sarcomas, and melanomas, were grouped together; and all those with hematologic malignancies were divided into five categories: acute leukemias, myelodysplastic syndrome (MDS), chronic myeloproliferative neoplasms (essential thrombocythemia, polycythemia vera, chronic myeloid leukemia, idiopathic myelofibrosis), lymphomas (Hodgkin and non-Hodgkin), and plasma cell disorders. In total, 224,396 RBC units were transfused over the 4-year study period to all patients at our institution. Of those 224,396 units, 5576 (2.5%) RhD-positive units were delivered by transfusion to 936 RhD-negative oncology patients, and 391 (42%) patients were excluded because they lacked an RBC antibody screen obtained 28 days or 
Alloimmunization
Of 545 eligible individuals, 76 (14%) RhD-negative patients formed anti-D. Of these, 41 of 76 responders (54%) formed antibodies to other RBC antigens in addition to anti-D (Fig. 1) . Of the 469 patients who did not form anti-D, 12 (3%) formed an RBC antibody to another antigen(s), including anti-E, unidentified antibodies, or pan-reactivity. One responder and one nonresponder had a history of anti-K identified before the study dates. Among nonresponders, the average length of serologic follow-up from the first incompatible transfusion to the last negative RBC antibody screen was 324 days (range, 30-1733 days). Among responders, the average length of serologic follow-up from the first incompatible transfusion to the first positive RBC antibody screen was 303 days (range, 34-1557 days).
Clinical factors associated with alloimmunization
The primary oncologic diagnosis was significantly associated with responder status (p < 0.0001). Age, sex, ethnicity, and ABO group were not statistically significant ( Table 2) . The logistic regression model (Table 3) indicated that, even after adjusting for the number of RBC units transfused, patients who had MDS or solid malignancies were more likely to be responders than those who had acute leukemia (MDS: p 5 0.0337; OR, 3.435; 95% CI, 1.100-10.725; solid malignancy: p5 0.0071; OR, 2.9; 95% CI, 1.338-6.338). The demographic details of the 76 responders according to different diagnosis types are provided in 
DISCUSSION
This is the first and largest study examining alloimmunization to RhD-positive RBCs in oncology patients. There is an abundance of literature on RhD-incompatible platelet transfusions in oncology patients and RhDincompatible RBC transfusions in nononcology patients (Table 1) . However, only a few studies have been published on RhD-incompatible RBC transfusion, because it is not a common practice in the general patient population. Previous studies in oncology patients have demonstrated lower rates but have not definitely characterized diagnostic categories that are associated with anti-D formation after RBC transfusion in oncology patients.
We detected alloimmunization to the D antigen in 14% of patients in our study. Patients who had hematologic malignancies had a much lower rate of alloimmunization to RhD (7%) compared with patients who had solid malignancies (22.6%), perhaps because of impaired immune responses. Patients with MDS had an alloimmunization rate of 23%, which was the highest of all malignancy types examined. Previous studies 29, 30 in patients with MDS who received chronic transfusions reported high rates of alloimmunization (range, 15%-59%); however, those studies reported alloimmunization to antigens other than RhD, because all of their patients received ABO-matched and RhD-matched RBCs. The reason for predisposition to alloantibody formation in patients with MDS remains unknown. Although it was not statistically significant, the alloimmunization rate in patients with multiple myeloma was high (16%) and should be investigated with larger sample sizes. Transfusion-induced alloimmunization is thought to be dependent on dose of transfusion, immunogenicity of the antigen, and patient-related variables. Bauer and colleagues observed that female sex was associated with a higher alloimmunization rate 31 ; however, a recent metaanalysis 32 attributed the generally higher post-transfusion response rate in women to more allogeneic exposure, especially from pregnancy. Similarly, Ameen and colleagues reported that patient age may contribute to immune response. 33 Most alloimmunization occurred at ages 2 to 10 years, followed by ages 11 to 15 years, and 16 to 20 years, respectively. We did not identify age or sex as statistically significant in our study. In the current study, 54% of RhD-negative patients formed both anti-D and other alloantibodies compared with only 3% RhD-negative patients who did not form anti-D but formed other alloantibodies. This finding is similar to previously published studies suggesting that individuals who make anti-D also have increased chances of making antibodies to other antigens carried by the RhD-positive RBCs. 34, 35 In contrast to those earlier studies, Schonewille and Brand 36 found that the antibody response against strong RBC antigens like E and K does not enhance antibody formation against weaker antigens. However, the anti-D response was excluded in this study. The average number of incompatible RBCs transfused was higher in nonresponders, because nonresponders continued to receive RhD-incompatible RBCs, whereas responders were switched to Rh-compatible RBCs after anti-D formation.
There were several limitations of this study. One was that participants were not regularly tested for anti-D. The time to formation of anti-D in the responders was the time until their next hospital or clinic visit with an RBC antibody screen. The exact time of antibody formation in patients who had subsequent positive screens is unknown. Similarly, the assumption that a patient with subsequent negative RBC antibody screens would remain negative in the future is unreliable. Another limitation was the exclusion of RhD-incompatible blood products other than RBCs. The majority of platelets transfused at our institution are whole blood-derived. However, we previously reported a lack of alloimmunization to RhDincompatible platelets in our patients. 13 With regard to granulocytes, we routinely drain out the RBCs by gravity sedimentation after the addition of hydroxyethyl. On average, the hematocrit after draining is less than 1.5%. Although this is low, there is still some potential for anti-D formation. 37 The lower rate of anti-D formation in oncology patients is due to the immunosuppressant effects of chemotherapy. In a study of 50 pediatric patients with acute lymphoblastic leukemia who were receiving immunosuppressive chemotherapy, an association was observed that (16) Chemotherapy (1) Immunosuppressive (2) No chemotherapy (9) No treatment (22) No chemotherapy (10) No chemotherapy (2) * Miscellaneous carcinomas include mesothelioma, desmoplastic small round cell tumor, and malignant epithelial tumor. AML 5 acute myeloid leukemia; Ca 5 carcinoma; APL 5 acute promyelocytic leukemia; ALL 5 acute lymphoblastic leukemia; GI 5 gastrointestinal; Gyn 5 gynecologic; Chemo 5 chemotherapy.
resulted in reduced IgG and IgM levels.study 39 was done in pediatric patients, in which alloimmunization rates in were compared between oncology and nononcology patients. Those authors reported that, although the frequency of alloimmunization was lower in children who received chemotherapy (0.3%), it was not significantly different from medical and surgical pediatric patients with nonhemoglobinopathies (1.3%).
Hematologic malignancies have lower rates of alloimmunization than solid malignancies, and this may be caused by lymphocyte impairment of the disease. It is unclear why MDS had the highest rates of anti-D formation, although previous studies have detected higher rates of alloimmunization to antigens other than RhD in patients with MDS. 29, 30 It is intriguing that 43% of responders received chemotherapy. Unfortunately, we do not know how many of the nonresponders were receiving chemotherapy, which is another limitation of the current study. Future studies on RBC alloimmunization may help describe the immunosuppressive results of different chemotherapy regimens.
CONCLUSIONS
We measured a lower rate of alloimmunization to the D antigen in our population of RhD-negative patients with cancer (14%) compared with the general patient population (22%). 16 The rate of alloimmunization was higher in patients who had solid cancers (22.6%) or MDS (23%) compared with those who had other hematologic malignancies (7%). Knowledge of cancer diagnoses that predispose to RhD alloimmunization helps develop strategies to identify patients at higher risk of anti-D formation. This can aid RhD-negative RBC utilization and result in better availability of RhD-negative units for younger female oncology patients.
